Answers are grounded in this paper and cite their sources.
Antigen-directed T cell cancer immunotherapy is increasingly shifting toward combination regimens with complementary mechanisms to enhance efficacy without exacerbated toxicity. However, rationally designing efficient combination strategies in this realm remains a challenge. Herein, we engineered a sono-destructive and clinically approved β-amino ester random copolymer (PBAE) nanoplatform that integrates sonosensitizers and interleukin-12 (IL-12) to spatially and temporally regulate antitumor immunity. The PBAE polymer features a thioacetal backbone that enables ultrasound (US)-triggered complete fragmentation, allowing for precise and rapid spread of tumor antigens, immunogenic molecules, and a single low dose of IL-12 (one-tenth of the high doses typically used for therapeutic benefit). In a preclinical human papillomavirus (HPV) 16 oncoproteins E6/E7-expressing tumor model, this combination therapy demonstrates superior antitumor efficacy alongside a robust safety profile. Mechanistically, US-mediated in situ vaccination activates multiple subsets of dendritic cells (DCs), including conventional type I DC (cDC1), cDC2, monocyte-derived DCs, and plasmacytoid DCs, enhancing the presentation of released E7 antigens to prime T cells. IL-12 further amplifies the cytotoxic activity of E7-specific CD8+ T cells and drives the differentiation of T helper 1 cells, complementing therapeutic effect through increased production of cytotoxic enzymes, and cytokines. This work presents an advanced combination regimen for streamlined cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: